Acadian Asset Management
TARS icon

Acadian Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Acadian Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,480
Closed -$93K – 1913
2022
Q3 		$93K Sell
5,480
-13,197
-71% -$210K ﹤0.01% 1384
2022
Q2 		$272K Buy
+18,677
New +$280K ﹤0.01% 1124

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management's TARS Position: Q4 2022 in Review

Acadian Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2022, closing a stake of 5,480 shares — an estimated $93K sold.

Acadian Asset Management first reported a position in TARS in Q2 2022 and held it in 2 quarters. The position peaked at $272K in Q2 2022. 69 funds tracked by Wall St. Rank hold TARS as of Q4 2022.

  • Acadian Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Acadian Asset Management sold 5,480 Tarsus Pharmaceuticals shares in Q4 2022, an estimated $93K.
  • Acadian Asset Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Acadian Asset Management's Tarsus Pharmaceuticals position peaked at $272K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2022.

Based on Acadian Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.